Precigen (PGEN) Stock Forecast & Price Target

Precigen is a biopharmaceutical company specializing in precision medicines for immuno-oncology, autoimmune disorders, and infectious diseases. Their key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for manufacturing. They have a strong pipeline with four clinical programs and potential for label expansion in multiple indications. The recent launch of their drug, Papzimeos, has performed well, with sales exceeding expectations and plans for label expansion and further clinical studies. Their financials are strong, with a projected net loss of $0.02 per diluted share in FY2026 and cash reserves to fund operations through cash flow break even in 4Q26.

Precigen is facing challenges in their development programs, as evidenced by a delay in the launch of their first commercial product, Papzimeos, from 1H26 to 2H26. They are also highly dependent on the success of this single product, with limited offerings in their clinical pipeline. Furthermore, increased operational expenses and lower gross margins may negatively affect their financials in the near future.